tiprankstipranks
Trending News
More News >
Ehealth (EHTH)
NASDAQ:EHTH

Ehealth (EHTH) AI Stock Analysis

Compare
1,036 Followers

Top Page

EHTH

Ehealth

(NASDAQ:EHTH)

Select Model
Select Model
Select Model
Neutral 55 (OpenAI - 5.2)
Rating:55Neutral
Price Target:
$1.50
▼(-3.85% Downside)
Action:ReiteratedDate:03/04/26
The score is primarily held back by weak cash generation and bearish technicals (downtrend across moving averages with negative MACD). Offsetting factors include improving profitability and a constructive earnings-call outlook focused on cost reductions and a path toward breakeven/positive operating cash flow, though 2026 is expected to see lower revenue and continued industry pressure.
Positive Factors
Medicare segment strength
eHealth's core Medicare business shows durable revenue and profit growth, with higher gross profit and scale in Medicare products. That recurring, retention-linked revenue base and improving Medicare LTV supports stable long-term cashflows and defensible market position versus nonrecurring channels.
Improving profitability and margins
Recent multi-year margin expansion and a material return to GAAP profitability indicate structural cost and mix improvements. Sustained higher EBITDA margins create durable internal funding for product investment and debt reduction, improving financial resilience if execution continues.
Stronger liquidity and balance-sheet actions
Replacing costly term debt with a $125M ABL and repaying prior loans materially improves near-term liquidity and lowers financing risk. The facility provides flexible capacity for working capital, AI/tech investments and to bridge commissions timing variability, supporting strategic initiatives.
Negative Factors
Weak cash generation
Persistent negative operating and free cash flow, despite reported profits, signals earnings are not yet reliably converting to cash. This structural cash shortfall raises dependence on external liquidity, constrains reinvestment, and heightens execution risk if commissions timing or receivables deteriorate.
Industry commission pressure
Ongoing commission suppression and carrier plan exits are a structural headwind to eHealth's commission-driven model. Reduced carrier sponsorships and narrower distribution increase customer acquisition costs and compress long-term unit economics unless offset by diversification or higher-margin products.
Planned revenue pullback (bridge year)
Deliberately accepting lower 2026 revenue to focus on margin/cash is a structural trade-off: it reduces near-term market share and scale benefits. If cost cuts or product shifts underdeliver, the company may face prolonged growth drag and tougher path to regain top-line momentum.

Ehealth (EHTH) vs. SPDR S&P 500 ETF (SPY)

Ehealth Business Overview & Revenue Model

Company DescriptioneHealth, Inc. operates a health insurance marketplace that provides consumer engagement, education, and health insurance enrollment solutions in the United States. The company operates in two segments, Medicare; and Individual, Family and Small Business. Its ecommerce platforms organize and present health insurance information in various formats that enable individuals, families, and small businesses to research, analyze, compare, and purchase a range of health insurance plans. The company operates a marketplace that offers consumers a choice of insurance products, such as Medicare Advantage, Medicare Supplement, Medicare Part D prescription drug, individual and family, small business, and other ancillary health insurance products from health insurance carriers. It markets health insurance plans through its websites, including eHealth.com, eHealthInsurance.com, eHealthMedicare.com, Medicare.com, PlanPrescriber.com, and GoMedigap.com, as well as through a network of marketing partners. The company also licenses its health insurance ecommerce technology that enables health insurance carriers to market and distribute health insurance plans online; and provides online sponsorship and advertising, and lead referral services. eHealth, Inc. was incorporated in 1997 and is headquartered in Santa Clara, California.
How the Company Makes MoneyEhealth generates revenue primarily through commissions earned from insurance carriers for each policy sold through its platform. The company acts as an intermediary, facilitating the enrollment of customers into various health insurance plans and receiving a percentage of the premium paid by the insured. Additionally, Ehealth may earn revenue from lead generation services by providing potential customer data to insurance providers. The company's partnerships with numerous insurance carriers enhance its offerings and improve its competitive position in the market, while its online platform also allows for scalability and cost-efficiency in its operations.

Ehealth Earnings Call Summary

Earnings Call Date:Feb 25, 2026
(Q4-2025)
|
% Change Since: |
Next Earnings Date:May 12, 2026
Earnings Call Sentiment Positive
The call highlighted meaningful progress on profitability, LTV improvement, technology innovation and ancillary product momentum, with full-year adjusted EBITDA up 40%, GAAP net income nearly quadrupling, Medicare LTV and margins improving, and large commissions receivable. Management candidly framed 2026 as a deliberate 'bridge year' in which they will accept lower revenue and enrollment to prioritize operating cash flow, margin improvement and strategic investments (expanded ancillaries, ICHRA/SaaS, AI). Industry headwinds such as commission suppression, plan eliminations and sponsorship declines create near-term top-line pressure and execution risks, but management has clear cost-reduction targets (approximately $30M fixed and >$60M variable savings) and liquidity actions to support the transition. Overall, positive operational momentum and disciplined capital allocation outweigh short-term revenue headwinds.
Q4-2025 Updates
Positive Updates
Revenue Growth
Total revenue for fiscal 2025 was $554.0M, up 4% year-over-year; Q4 2025 revenue was a company record $326.2M, up 4% year-over-year.
Material Improvement in Profitability
Full year GAAP net income rose to $40.0M, nearly 4x the prior year (vs $10.1M in 2024); full year adjusted EBITDA increased 40% to $97.3M; Q4 adjusted EBITDA was $132.9M, up 10% year-over-year.
Medicare Segment Strength
Full year Medicare revenue was $531.2M, up 6% year-over-year; Q4 Medicare revenue was $319.6M, up 5% year-over-year; Q4 Medicare gross profit grew 12% to $178.3M and full year Medicare gross profit grew 21%.
Improved LTV and Efficiency
Medicare Advantage LTV increased 11% in Q4 2025; LTV to CAC ratio improved to 2.2x in Q4 from 2.0x a year earlier, indicating better long-term economics and higher enrollment margins.
Record Commissions Receivable
Total commissions receivable at December 31, 2025 were $1.1B, up 12% year-over-year, representing a record high balance and underlying cash-collection potential.
Ancillary Product Momentum
Hospital indemnity plan (HIP) approved application volume surged over 400% year-over-year in Q4; 2025 annual approved HIP members exceeded 30,000 (more than 5x 2024); Medicare Supplement approved applications rose 39% in Q4.
Operational and Cost Discipline
Management implemented actions expected to reduce fixed operating costs by ~$30M in 2026 (~20% lower fixed costs vs 2025) and reduce variable spend by over $60M, targeting overall spend reductions >$90M year-over-year.
AI and Technology Differentiation
An AI screener piloted earlier in the year was scaled during AEP, reducing wait times and performing on par or better than human screeners on transfer rates and conversions, positioning additional AI applications as a competitive advantage.
Capital and Liquidity Actions
Augmented liquidity via a $125M revolving credit facility (net of transaction costs) and repaid $70.7M of existing term loan; year-end cash, equivalents and marketable securities were $77.2M.
Negative Updates
Expected Revenue and Enrollment Moderation in 2026
Management expects Medicare enrollment volumes and noncommission revenue to decline in 2026 versus 2025 as they prioritize operating cash flow and margin; 2026 revenue guidance of $405M–$445M implies a meaningful decline from 2025's $554M.
Decline in Agency Submissions
Medicare Advantage submissions in the agency model declined 3% in Q4 2025, reflecting a strategic pullback in lower-margin third-party channels and a shift toward branded channels.
Pressure on Carrier-Driven Revenue Streams
Carrier dedicated revenue and sponsorships declined year-over-year in Q4 2025 due to industry-wide commission suppression, plan eliminations and carrier market exits; BPO and sponsorship revenue declines are expected to be factored into 2026 guidance.
Employer & Individual Segment Weakness
Employer and Individual segment revenue and profit decreased in both Q4 and full year 2025 as the segment transitions toward ICHRA and employer-focused solutions, creating near-term revenue headwinds.
Q4 GAAP Net Income Dip
Q4 2025 GAAP net income was $87.2M, down from $97.5M in Q4 2024, primarily due to a higher effective tax rate despite higher revenue in the quarter.
Cash and Timing Risk
Year-end cash balance was $77.2M vs $82.2M a year earlier; business cash flows are sensitive to timing of carrier commission payments, and 2026 operating cash flow guidance ranges from negative $10M to positive $12M, reflecting some material timing/risk uncertainty.
Tail Revenue Variability
Q4 positive net adjustment (tail) revenue was $3.9M vs $7.6M a year ago; while full year 2025 tail revenue grew to $44.4M (from $22.7M), future tail recognition is variable and guidance assumes $0–$20M of positive net adjustments in 2026.
Persistent Market Disruption and Commission Suppression
Management expects the Medicare Advantage structural reset to persist into 2026 with ongoing commission pressure, plan exits and narrowed carrier distribution relationships, limiting near-term growth opportunities.
Planned Pullback May Limit Near-Term Growth
The company is proactively reducing spend in lower-margin channels and accepting lower 2026 enrollment/revenue as a 'bridge year' trade-off to improve margins and cash flow, which could temper growth momentum.
Company Guidance
eHealth guided 2026 total revenue of $405M–$445M, GAAP net income of $8M–$25M, adjusted EBITDA of $55M–$75M, and operating cash flow of –$10M to $12M (assuming positive net adjustment/tail revenue of $0–$20M); management expects Medicare enrollment volumes and non‑commission revenue to decline vs. 2025 while earnings excluding net adjustments remain roughly flat and EBITDA margin ex‑tail improves. Actions driving the outlook include ~ $30M (≈20%) of fixed cost savings, >$60M of variable spend reductions (total spend cuts >$90M), a targeted ~ $25M year‑over‑year improvement in operating cash flow at the midpoint and breakeven operating cash flow in 2026 with positive operating cash flow targeted for 2027; commissions receivable are expected to remain around current levels entering 2027.

Ehealth Financial Statement Overview

Summary
Income statement and balance sheet show a meaningful profitability recovery and manageable leverage, but persistent negative operating and free cash flow (including 2025) is a major constraint and raises questions about earnings quality and durability.
Income Statement
72
Positive
Profitability has improved materially versus the 2021–2023 loss period, with 2024 returning to positive earnings and 2025 expanding margins further (net margin ~7.2% vs ~1.9% in 2024; EBITDA margin ~12.0% vs ~8.8%). Revenue growth also accelerated sharply in 2025 (+203.6%), though that step-change looks unusual versus the prior, steadier growth rates and warrants monitoring for sustainability. A key weakness is inconsistency over time (strong profit in 2020, deep losses in 2021–2022, then recovery), indicating earnings volatility.
Balance Sheet
74
Positive
Leverage appears manageable, with debt-to-equity staying relatively low (about 0.23 in 2025 and ~0.16 in 2024), supporting financial flexibility. Returns on equity have improved from negative in 2021–2023 to positive in 2024–2025 (~6.8% in 2025), consistent with the earnings recovery. The main concern is the notable drop in equity from 2023 to 2024 (despite improving profitability), which suggests balance-sheet volatility and reduces the margin of safety if operating results soften.
Cash Flow
33
Negative
Cash generation is the weakest area: operating cash flow and free cash flow are negative across all shown years, including 2025 (operating cash flow about -$25.3M; free cash flow about -$25.3M). While the size of the cash burn is smaller than the very weak 2020–2021 period, it still indicates the business is not yet consistently converting reported profits into cash. Free cash flow growth is also negative in 2025 and 2024, signaling deterioration rather than stabilization.
BreakdownDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue554.01M532.41M452.87M405.36M538.20M
Gross Profit540.25M530.62M451.10M403.71M536.21M
EBITDA83.25M46.81M295.00K-77.65M-105.18M
Net Income40.04M10.06M-28.21M-88.72M-104.38M
Balance Sheet
Total Assets1.26B1.16B1.11B1.11B1.15B
Cash, Cash Equivalents and Short-Term Investments77.22M82.24M121.65M144.40M123.23M
Total Debt134.35M96.92M103.16M106.80M41.37M
Total Liabilities288.82M567.00M209.26M461.66M399.77M
Stockholders Equity973.65M588.43M904.08M650.96M749.52M
Cash Flow
Free Cash Flow-27.59M-31.22M-17.47M-42.38M-183.48M
Operating Cash Flow-25.34M-18.37M-6.69M-26.87M-162.62M
Investing Cash Flow25.43M-48.42M-15.89M25.86M-12.63M
Financing Cash Flow34.29M-9.67M-6.22M63.84M213.24M

Ehealth Technical Analysis

Technical Analysis Sentiment
Negative
Last Price1.56
Price Trends
50DMA
2.58
Negative
100DMA
3.46
Negative
200DMA
3.74
Negative
Market Momentum
MACD
-0.26
Negative
RSI
39.86
Neutral
STOCH
41.76
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For EHTH, the sentiment is Negative. The current price of 1.56 is above the 20-day moving average (MA) of 1.55, below the 50-day MA of 2.58, and below the 200-day MA of 3.74, indicating a neutral trend. The MACD of -0.26 indicates Negative momentum. The RSI at 39.86 is Neutral, neither overbought nor oversold. The STOCH value of 41.76 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for EHTH.

Ehealth Risk Analysis

Ehealth disclosed 43 risk factors in its most recent earnings report. Ehealth reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Ehealth Peers Comparison

Overall Rating
UnderperformOutperform
Sector (68)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
68
Neutral
$18.00B11.429.92%3.81%9.73%1.22%
56
Neutral
$114.62M0.9513.52%13.16%
55
Neutral
$48.47M3.504.33%16.79%
46
Neutral
$16.75M0.174.56%19.30%-17.56%
44
Neutral
$25.59M-0.09-142.05%7.56%-344.04%
* Financial Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
EHTH
Ehealth
1.56
-6.12
-79.69%
HUIZ
Huize Holding
1.66
-1.61
-49.24%
SLQT
SelectQuote
0.65
-2.95
-81.94%
GOCO
GoHealth
1.59
-11.98
-88.28%

Ehealth Corporate Events

Business Operations and StrategyPrivate Placements and Financing
eHealth Secures New Credit Facility and Amends Preferred Stock
Positive
Jan 6, 2026

On January 6, 2026, eHealth announced that its subsidiary eHealthInsurance Services, Inc. entered into a new $125 million asset-based revolving credit facility with Manulife | Comvest Credit Partners, replacing its higher-cost term loan from Blue Torch Finance. The three-year facility, priced at SOFR plus 6.50%, features a flexible borrowing base with the potential to expand funding by up to $50 million, and part of the proceeds has already been used to fully repay roughly $70 million outstanding under the prior Blue Torch loan and related fees. The remaining capital is earmarked to support strategic growth initiatives, including investment in AI-driven capabilities, omni-channel technology and revenue diversification, while eHealth pursues further capital structure improvements, addresses its convertible Series A preferred stock, and enhances governance through a new Strategy Committee, underscoring a broader effort to strengthen its balance sheet and long-term competitive positioning. In connection with the facility, the company also amended its investment agreement with the holder of its convertible Series A preferred stock, signaling continued focus on aligning financing terms with its long-term value creation plans.

The most recent analyst rating on (EHTH) stock is a Hold with a $5.50 price target. To see the full list of analyst forecasts on Ehealth stock, see the EHTH Stock Forecast page.

Business Operations and StrategyFinancial DisclosuresRegulatory Filings and Compliance
EHealth Raises 2025 Guidance After Strong Medicare Enrollment
Positive
Dec 18, 2025

On December 16, 2025, eHealth’s board adopted amended and restated bylaws, effective immediately, that adjust shareholder meeting notice deadlines to Eastern Time, refine rules for stockholder director nominations, define “principal competitor” for disclosure purposes, and clarify the company’s ability to maintain insurance for its directors, officers, employees, and agents, along with other technical and conforming updates. On December 18, 2025, the company reported that its latest Medicare Annual Enrollment Period delivered enrollments and revenue in line with expectations but stronger-than-anticipated profitability, supported by a shift toward higher-quality direct branded channels and the deployment of AI screeners to improve marketing yield and sales efficiency, and it raised full-year 2025 guidance for total revenue, GAAP net income, and adjusted EBITDA, while modestly trimming the upper end of its operating cash flow outlook, signaling improved earnings power and tighter operational discipline for investors and other stakeholders.

The most recent analyst rating on (EHTH) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on Ehealth stock, see the EHTH Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Mar 04, 2026